NuGen Medical Devices Azioni (OTC: NGMDF)

Ultime notizie per NuGen Medical Devices (OTC:NGMDF) Azioni

NuGen Medical Devices Inc is a medical device manufacturing company specializing in the field of needleless injections and related technologies. The reportable segment of the company is the manufacturing of needless injector devices. Geographically the company generates revenue from Europe followed by Asia, North America and others.

NUGEN MED DEVICES INC by NUGEN MED DEVICES INC.

NuGen Medical Devices Inc

Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.37) by 29.73 percent. The company reported quarterly sales of $26.03 million which missed the analyst consensus estimate of $34.37 million by 24.26 percent. This is a 74.03 percent increase over sales of $14.96 million the same period last year.

Earnings

Earnings Misses

News

ACLX

Arcellx Q3 2024 GAAP EPS $(0.48) Misses $(0.37) Estimate, Sales $26.03M Miss $34.37M Estimate

Management

Natural Gas Services Group Announced The Appointment Of Ian Eckert As CFO Effective No Later Than January 5th, 2026. NGS's Current Interim CFO John Bittner Will Continue In that Role Until Mr. Eckert's Start Date

Guidance

Con Edison CFO Kirk Andrews Says We Are Narrowing And Revising Our 2024 Adjusted EPS Guidance To The Upper Half Of Our Original Range

Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) sees Q4 sales of $40.000 million-45.000 million vs $50.03 million estimate.

CMBM

Cambium Networks Sees Q4 Sales $40.000M-45.000M vs $50.03M Est

SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.03 by 66.67 percent. The company reported quarterly sales of $97.400 million which beat the analyst consensus estimate of $96.647 million by 0.78 percent. This is a 23.73 percent increase over sales of $78.718 million the same period last year.

Earnings Beats

SEMR

SEMrush Hldgs Q3 2024 GAAP EPS $0.01 Misses $0.03 Estimate, Sales $97.400M Beat $96.647M Estimate

Sandstorm Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) reported quarterly sales of $44.700 which missed the analyst consensus estimate of $44.900 million by 100.00 percent. This is a 100.00 percent decrease over sales of $41.324 million the same period last year.

SAND

Sandstorm Gold Q3 Sales $44.700 Miss $44.900M Estimate

nLight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $56.13 million which beat the analyst consensus estimate of $55.27 million by 1.55 percent. This is a 10.85 percent increase over sales of $50.63 million the same period last year.

LASR

nLight Q3 Adj $(0.08), Inline, Sales $56.13M Beat $55.27M Estimate

Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) is looking for Q2 Adj EPS of $0.30-0.40 vs $0.27 analyst estimate. sees sales of $380.000 million-400.000 million vs $354.32 million estimate.

LITE

Lumentum Holdings Sees Q2 Adj EPS $0.30-0.40 vs $0.27 Est; Sees Sales $380.000M-400.000M vs $354.32M Est

Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.62 by 3.7 percent.

Consolidated Edison Q3 2024 Adj. EPS $1.68 Beats $1.62 Estimate

PDF Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDFS#NASDAQ">PDFS</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.20 by 25 percent. The company reported quarterly sales of $46.409 million which beat the analyst consensus estimate of $46.196 million by 0.46 percent. This is a 9.58 percent increase over sales of $42.350 million the same period last year.

PDFS

PDF Solutions Q3 2024 Adj. EPS $0.25 Beats $0.20 Estimate, Sales $46.409M Beat $46.196M Estimate

TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) affirms FY2024 sales outlook from $74.50 million-76.50 million to $74.50 million-76.50 million.

TELA

TELA Bio Affirms FY2024 Sales Guidance from $74.50M-76.50M to $74.50M-76.50M

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2025 Product sales outlook from $450.00 million-475.00 million to $450.00 million-475.00 million.

IOVA

Iovance Biotherapeutics Affirms FY2025 Product Sales Guidance from $450.00M-475.00M to $450.00M-475.00M

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) raises FY2024 sales outlook from $580.00 million-595.00 million to $620.00 million-635.00 million.

COLL

Collegium Pharmaceutical Raises FY2024 Sales Guidance from $580.00M-595.00M to $620.00M-635.00M  VS Est.625.37M

CPAY

Corpay Expects Q4 Total Revenues Of $1.04B - $1.07B, Adjusted EP Of $5.25 - $5.45

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2024 Product sales outlook from $160.00 million-165.00 million to $160.00 million-165.00 million.

Iovance Biotherapeutics Affirms FY2024 Product Sales Guidance from $160.00M-165.00M to $160.00M-165.00M

AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.05 by 20 percent. This is a 33.33 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $82.68 million which missed the analyst consensus estimate of $92.83 million by 10.93 percent. This is a 10.60 percent decrease over sales of $92.48 million the same period last year.

ASLE

AerSale Q3 Adj $0.04 Misses $0.05 Estimate, Sales $82.68M Miss $92.83M Estimate

Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. The company reported quarterly sales of $7.855 million which beat the analyst consensus estimate of $4.215 million by 86.37 percent. This is a 180.74 percent increase over sales of $2.798 million the same period last year.

AMPX

Amprius Technologies Q3 2024 GAAP EPS $(0.10) Beats $(0.13) Estimate, Sales $7.855M Beat $4.215M Estimate

Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) sees Q4 sales of $6.000 million-6.300 million vs $5.95 million estimate.

INVE

Identiv Sees Q4 Sales $6.000M-6.300M vs $5.95M Est

Fourth Quarter 2024 Outlook
For the fourth quarter 2024, the Company expects:
<ul>
<li>Revenue growth on a constant currency basis in the range of 10.3%-13.3%. This represents revenue in the range of $375-$385 million, assuming FX rates remain relatively stable with the end of Q3.&nbsp;</li>
<li>Adjusted EBITDA in the range of $9-$14 million, representing an Adjusted EBITDA Margin in the range of 2.4%-3.6%.&nbsp;</li>
</ul>

WBTN

WEBTOON Entertainment Sees Q4 Revenue Growth On A Constant Currency Basis In The Range Of 10.3%-13.3% ($375M-$385M) Vs $375.92M Est.

Tidewater Sees 2024 Revenue $1.33B-$1.35B vs $1.39B Est.

NuGen Medical has a needle-free injecting device approved in 40+ countries. Sales are ramping up slowly, but weight loss drug could be a game-changer.

Comments

NuGen Medical Devices

Notizie

Ultime notizie per NuGen Medical Devices (OTC:NGMDF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO